tbuckley/cabot-search huggingface dataset:
Incidence of primary cutaneous T-cell lymphoma in Wales
Authors: R.A. Abbott, C. Aldridge, S. Dojcinov, V. Piguet
Journal: British Journal of Dermatology (2013)

Journal Article Incidence of primary cutaneous T‐cell lymphoma in Wales Get access R.A. Abbott, R.A. Abbott Department of Dermatology University Hospital of Wales Heath Park Cardiff CF14 4XW U.K Search for other works by this author on: Oxford Academic Google Scholar C. Aldridge, C. Aldridge Department of Dermatology Prince Charles Hospital Merthyr Tydfil U.K Search for other works by this author on: Oxford Academic Google Scholar S. Dojcinov, S. Dojcinov Department of Histopathology University Hospital of Wales Heath Park Cardiff CF14 4XW U.K Search for other works by this author on: Oxford Academic Google Scholar V. Piguet V. Piguet Department of Dermatology University Hospital of Wales Heath Park Cardiff CF14 4XW U.KInstitute of Infection and Immunity Cardiff University School of Medicine Cardiff U.K Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 169, Issue 6, 1 December 2013, Pages 1366–1367, https://doi.org/10.1111/bjd.12516 Published: 01 December 2013
Involvement of CXCR4/CXCR7/CXCL12 Interactions in Inflammatory Bowel Disease
Authors: Lael Werner, Hanan Guzner-Gur, Iris Dotan
Journal: Theranostics (2013)

Directional movement of cells in the human body is orchestrated via chemokines. This migration was initially identified in pathological and immunological processes but quickly extended to homeostatic cell trafficking. One such chemokine is the ubiquitous CXCL12 (initially called SDF1-α) which signals via the chemokine receptors CXCR4 and CXCR7. In the last decade CXCL12 was recognized to participate not only in embryonic development and homeostatic maintenance, but also in progression of inflammation. A role for CXCL12 and its receptors CXCR4 and CXCR7 in inflammatory bowel diseases was recently shown. The current review discusses up to date knowledge of CXCL12 in inflammation, focusing on the involvement of CXCL12 and its receptors, CXCR4 and CXCR7, in inflammatory bowel diseases.
Role of RhoB in the Regulation of Pulmonary Endothelial and Smooth Muscle Cell Responses to Hypoxia
Authors: Beata Wojciak-Stothard, Lan Zhao, Eduardo Oliver, Olivier Dubois, Yixing Wu, Dimitris Kardassis, Eleftheria Vasilaki, Minzhou Huang, Jane A. Mitchell, Louise S. Harrington, George C. Prendergast, Martin R. Wilkins
Journal: Circulation Research (2012)

Rationale: RhoA and Rho kinase contribute to pulmonary vasoconstriction and vascular remodeling in pulmonary hypertension. RhoB, a protein homologous to RhoA and activated by hypoxia, regulates neoplastic growth and vasoconstriction but its role in the regulation of pulmonary vascular function is not known. Objective: To determine the role of RhoB in pulmonary endothelial and smooth muscle cell responses to hypoxia and in pulmonary vascular remodeling in chronic hypoxia-induced pulmonary hypertension. Methods and Results: Hypoxia increased expression and activity of RhoB in human pulmonary artery endothelial and smooth muscle cells, coincidental with activation of RhoA. Hypoxia or adenoviral overexpression of constitutively activated RhoB increased actomyosin contractility, induced endothelial permeability, and promoted cell growth; dominant negative RhoB or manumycin, a farnesyltransferase inhibitor that targets the vascular function of RhoB, inhibited the effects of hypoxia. Coordinated activation of RhoA and RhoB maximized the hypoxia-induced stress fiber formation caused by RhoB/mammalian homolog of Drosophila diaphanous-induced actin polymerization and RhoA/Rho kinase-induced phosphorylation of myosin light chain on Ser19. Notably, RhoB was specifically required for hypoxia-induced factor-1α stabilization and for hypoxia- and platelet-derived growth factor-induced cell proliferation and migration. RhoB deficiency in mice markedly attenuated development of chronic hypoxia-induced pulmonary hypertension, despite compensatory expression of RhoA in the lung. Conclusions: RhoB mediates adaptational changes to acute hypoxia in the vasculature, but its continual activation by chronic hypoxia can accentuate vascular remodeling to promote development of pulmonary hypertension. RhoB is a potential target for novel approaches (eg, farnesyltransferase inhibitors) aimed at regulating pulmonary vascular tone and structure.
Satisfaction After Contralateral Prophylactic Mastectomy: The Significance of Mastectomy Type, Reconstructive Complications, and Body Appearance
Authors: Marlene H. Frost, Jeffrey M. Slezak, Nho V. Tran, Constance I. Williams, Joanne L. Johnson, John E. Woods, Paul M. Petty, John H. Donohue, Clive S. Grant, Jeff A. Sloan, Thomas A. Sellers, Lynn C. Hartmann
Journal: Journal of Clinical Oncology (2005)

Contralateral prophylactic mastectomy (CPM) is one option for reducing the risk of a second breast cancer in women with a personal and family history of breast cancer. Few data are available regarding satisfaction, psychological, and social function after CPM. The purpose of this research is to evaluate women's long-term satisfaction with CPM, factors influencing satisfaction, and psychological and social function after CPM.This was a descriptive study of all women with a family history of breast cancer, known to be alive, who elected CPM at Mayo Clinic (Rochester, MN) between 1960 and 1993 (n = 621). Ninety-four percent of the women (n = 583) completed a study-specific questionnaire.A mean of 10.3 years after the procedure, the majority of women (83%) were satisfied with their CPM. A smaller number were neutral (8%) or dissatisfied (9%). Women who had a subcutaneous mastectomy had more problems with reconstruction, and fewer of these women were satisfied than women with simple mastectomy. Decreased satisfaction with CPM was associated with decreased satisfaction with appearance, complications with reconstruction, reconstruction after CPM, and increased level of stress in life. The majority of women experienced no change or favorable effects in self-esteem (83%), level of stress in life (83%), and emotional stability (88%). Satisfaction with body appearance, feelings of femininity, and sexual relationships were the most adversely affected with 33%, 26%, and 23% of the women responding negatively.Although most women are satisfied with CPM, each woman should weigh the benefits alongside the potential adverse effects.
Cancer prevalence estimates in Europe at the beginning of 2000
Authors: G. Gatta, S. Mallone, J.M. van der Zwan, A. Trama, S. Siesling, R. Capocaccia, M. Hackl, E. Van Eycken, K. Henau, G. Hedelin, M. Velten, G. Launoy, A.V. Guizard, A.M. Bouvier, M. Maynadié, A.-S. Woronoff, A. Buemi, M. Colonna, O. Ganry, P. Grosclaude;, B. Holleczek, H. Ziegler, L. Tryggvadottir, F. Bellù, S. Ferretti, D. Serraino, L. Dal Maso, E. Bidoli, S. Birri, A. Zucchetto, L. Zainer, M. Vercelli, M.A. Orengo, C. Casella, A. Quaglia, M. Federico, I. Rashid, C. Cirilli, M. Fusco, A. Traina, M. Michiara, V. De Lisi, F. Bozzani, A. Giacomin, R. Tumino, M.G. La Rosa, E. Spata, A. Signora, L. Mangone, F. Falcini, S. Giorgetti, A. Ravaioli, G. Senatore, A. Iannelli, M. Budroni, S. Piffer, S. Franchini, E. Crocetti, A. Caldarella, T. Intrieri, F. La Rosa, F. Stracci, T. Cassetti, P. Contiero, G. Tagliabue, P. Zambon, S. Guzzinati, F. Berrino, P. Baili, F. Bella, R. Ciampichini, G. Gatta, C. Margutti, A. Micheli, P. Minicozzi, M. Sant, A. Trama, M. Caldora, R. Capocaccia, E. Carrani, R. De Angelis, S. Francisci, E. Grande, R. Inghelmann, H. Lenz, L. Martina, P. Roazzi, M. Santaquilani, A. Simonetti, A. Tavilla, A. Verdecchia, F. Langmark,, J. Rachtan, R. Mężyk, S. Góżdź, U. Siudowska, M. Zwierko, M. Bielska-Lasota, Ch. Safaei Diba, M. Primic-Zakelj, A. Mateos, I. Izarzugaza, A. Torrella Ramos, O. Zurriaga, R. Marcos-Gragera, M.L. Vilardell, A. Izquierdo, E. Ardanaz, C. Moreno-Iribas, J. Galceran, Å. Klint, M. Talbäck, G. Jundt, M. Usel, H. Frick, S.M. Ess, A. Bordoni, I. Konzelmann, S. Dehler, S. Siesling, O. Visser, R. Otter, J.W.W. Coebergh, D.C. Greenberg, J. Wilkinson, M. Roche, J. Verne, D. Meechan, J. Poole, G. Lawrence, A. Gavin, D.H. Brewster, R.J. Black, J.A. Steward
Journal: Annals of Oncology (2013)
Foxo3a Suppression of Urothelial Cancer Invasiveness through Twist1, Y-Box–Binding Protein 1, and E-Cadherin Regulation
Authors: Masaki Shiota, YooHyun Song, Akira Yokomizo, Keijiro Kiyoshima, Yasuhiro Tada, Hiroshi Uchino, Takeshi Uchiumi, Junichi Inokuchi, Yoshinao Oda, Kentaro Kuroiwa, Katsunori Tatsugami, Seiji Naito
Journal: Clinical Cancer Research (2010)

Abstract Purpose: Invasion and metastasis are key steps in the progression of urothelial cancer (UC) into a critical disease. Foxo3a is a member of the Foxo transcription factor family that modulates the expression of various genes. We aimed to elucidate the role of Foxo3a in UC invasion. Experimental Design: Foxo3a mRNA and protein expressions in UC samples were investigated by gene expression assays and immunohistochemistry, respectively. Foxo3a expression was compared with clinicopathologic characteristics and patient prognoses based on UC samples. Quantitative real-time polymerase chain reaction, Western blotting, and migration assays were also conducted in UC cells. Results: Foxo3a expression decreased in invasive UC; patients with low Foxo3a expression had poor disease-free survival, cancer-specific survival, and overall survival; Foxo3a knockdown in UC cells increased cellular motility. Foxo3a negatively regulated Twist1 and Y-box–binding protein 1 (YB-1), and positively regulated E-cadherin in KK47 and TCCsup cells that expressed Twist1, but not in T24 cells that did not express Twist1. Foxo3a-associated acetyltransferase p300 and Foxo3a acetylation status also affected UC motility. Conclusion: The results of this study indicate that Foxo3a regulates motility of UC through negative regulation of Twist1 and YB-1, and through positive regulation of E-cadherin. This suggests that Foxo3a could act as an independent prognostic factor in UC and could represent a promising molecular target for cancer therapeutics. Clin Cancer Res; 16(23); 5654–63. ©2010 AACR.
Cancer Stem Cells Are Enriched in the Side Population Cells in a Mouse Model of Glioma
Authors: Molly A. Harris, Hyuna Yang, Benjamin E. Low, Joydeep Mukherje, Abhijit Guha, Roderick T. Bronson, Leonard D. Shultz, Mark A. Israel, Kyuson Yun
Journal: Cancer Research (2008)

Abstract The recent identification of cancer stem cells (CSCs) in multiple human cancers provides a new inroad to understanding tumorigenesis at the cellular level. CSCs are defined by their characteristics of self-renewal, multipotentiality, and tumor initiation upon transplantation. By testing for these defining characteristics, we provide evidence for the existence of CSCs in a transgenic mouse model of glioma, S100β-verbB;Trp53. In this glioma model, CSCs are enriched in the side population (SP) cells. These SP cells have enhanced tumor-initiating capacity, self-renewal, and multipotentiality compared with non-SP cells from the same tumors. Furthermore, gene expression analysis comparing fluorescence-activated cell sorting–sorted cancer SP cells to non-SP cancer cells and normal neural SP cells identified 45 candidate genes that are differentially expressed in glioma stem cells. We validated the expression of two genes from this list (S100a4 and S100a6) in primary mouse gliomas and human glioma samples. Analyses of xenografted human glioblastoma multiforme cell lines and primary human glioma tissues show that S100A4 and S100A6 are expressed in a small subset of cancer cells and that their abundance is positively correlated to tumor grade. In conclusion, this study shows that CSCs exist in a mouse glioma model, suggesting that this model can be used to study the molecular and cellular characteristics of CSCs in vivo and to further test the CSC hypothesis. [Cancer Res 2008;68(24):10051–9]
Novel Therapeutic Strategy Against Central Baroreflex Failure
Authors: Takayuki Sato, Toru Kawada, Toshiaki Shishido, Masaru Sugimachi, Joe Alexander, Kenji Sunagawa
Journal: Circulation (1999)

Background —Central baroreflex failure in Shy-Drager syndrome and traumatic spinal cord injuries results in severe orthostatic hypotension and often confines the patient to the bed. We proposed a novel therapeutic strategy against central baroreflex failure: implementation of an artificial feedback control system able automatically to regulate sympathetic vasomotor tone, that is, a bionic baroreflex system (BBS). With the use of a rat model of central baroreflex failure, we developed the BBS and tested its efficacy. Methods and Results —Our prototype BBS for the rat consisted of a pressure sensor placed into the aortic arch, stimulation electrodes implanted into the greater splanchnic nerve, and a computer-driven neural stimulator. By a white noise approach for system identification, we first estimated the dynamic properties underlying the normal baroreflex control of systemic arterial pressure (SAP) and then determined how the BBS computer should operate in real time as the artificial vasomotor center to mimic the dynamic properties of the native baroreflex. The open-loop transfer function of the artificial vasomotor center was identified as a high-pass filter with a corner frequency of 0.1 Hz. We evaluated the performance of the BBS in response to rapid-progressive hypotension secondary to sudden sympathetic withdrawal evoked by the local imposition of a pressure step on carotid sinus baroreceptors in 16 anesthetized rats. Without the BBS, SAP rapidly fell by 49±8 mm Hg in 10 seconds. With the BBS placed on-line with real-time execution, the SAP fall was suppressed by 22±6 mm Hg at the nadir and by 16±5 mm Hg at the plateau. These effects were statistically indistinguishable from those of the native baroreflex system. Conclusions —These results suggest the feasibility of a BBS approach for central baroreflex failure.
Reasons Why Physicians Do Not Have Discussions About Poor Prognosis, Why It Matters, and What Can Be Improved
Authors: Jennifer W. Mack, Thomas J. Smith
Journal: Journal of Clinical Oncology (2012)

At a time of controversy about a sick and aging population and fiscal constraint, honest communication about choices and outcomes represents an important solution. Yet evidence consistently shows that doctors are hesitant to divulge prognostic information. We have found several underlying misconceptions held by health care professionals. Much of this work has been done in the cancer population but applies across serious illnesses.
Truck Driving and Bladder Cancer Mortality in Rural New England
Authors: S K Hoar, R Hoover
Journal: JNCI Journal of the National Cancer Institute (1985)

The relationship between truck driving and bladder cancer mortality was investigated in a case-control study in New Hampshire and Vermont. In-person interviews were conducted with the next-of-kin of 325 bladder cancer cases and 673 controls who died during 1975–1979. There were 35 cases and 53 controls who had ever been employed as truck drivers [odds ratio (OR) = 1.5, 95% confidence interval (Cl) = 0.9,2.6]. There was a statistically significant, but inconsistent, positive association between number of years of truck driving and the OR's, rising to 2.3 (1.2, 4.1) for 5 years or more of truck driving. Risk was greatest in men who began driving in the 1930's and 1940's (OR = 2.6, 95% Cl = 1.3, 5.1) and among residents of two of the most urbanized counties (OR = 3.0, 95% Cl = 1.2, 7.4). The association of bladder cancer with truck driving was unaffected by control for possible confounding factors, such as cigarette smoking and coffee drinking. It was not possible to determine whether the risks associated with truck driving were specifically due to diesel fumes. Truck drivers reporting diesel exposures had an OR = 1.8 (95% Cl = 0.5, 7.0), but those without diesel exposure still had an OR = 1.5 (95% Cl = 0.8, 2.7). Twenty-six cases and 39 controls reported exposure to diesel emissions in any occupation (OR = 1.5, 95% Cl = 0.8, 2.8), and a significant duration-response relationship was seen, rising to threefold for those employed in such jobs for 30–39 years.
William G Cahan Malcolm MacDonald Bell Geoffrey Shirley Jones Christopher (Kit) Lewthwaite Armand Lowenthal John Eugene Anthony O'Connell Robert Anthony O'Grady Pearson Edward Gordon Pyne Douglas Walter Quantrill Ernest Joseph Eric Topham Snehelata Vishwanath
Authors: J. H. Tanne, F. Stallerbrass, D. Galliford, M. Jacoby, P. Morris, R. M Vining, H. Hillman, R C. Connolly, J. Crowdy, J. Pyne, J Quantrill, J. Topham, K. Somers
Journal: BMJ (2001)

Antismoking advocate and thoracic surgeon New York (
IMMUNITY IN EXPERIMENTALLY INDUCED INFECTIOUS HEPATITIS
Authors: W. Paul Havens
Journal: The Journal of Experimental Medicine (1946)

1. 9 human volunteers, convalescent from infectious hepatitis experimentally induced by a strain of virus employed in this laboratory, were resistant when reinoculated with the same strain of virus, 6 to 9 months later. 2. 8 out of 12 previously healthy control subjects developed infectious hepatitis with jaundice following administration of this same material. 3. The demonstration of homologous immunity produced by this strain of virus is in agreement with the demonstration by others of homologous immunity produced by another strain of infectious hepatitis virus.
The Risk of Hemorrhage after Radiosurgery for Cerebral Arteriovenous Malformations
Authors: Keisuke Maruyama, Nobutaka Kawahara, Masahiro Shin, Masao Tago, Junji Kishimoto, Hiroki Kurita, Shunsuke Kawamoto, Akio Morita, Takaaki Kirino
Journal: New England Journal of Medicine (2005)

Angiography shows that stereotactic radiosurgery obliterates most cerebral arteriovenous malformations after a latency period of a few years. However, the effect of this procedure on the risk of hemorrhage is poorly understood.
Leptin Does Not Directly Affect CNS Serotonin Neurons to Influence Appetite
Authors: Daniel D. Lam, Gina M. Leinninger, Gwendolyn W. Louis, Alastair S. Garfield, Oliver J. Marston, Rebecca L. Leshan, Erica L. Scheller, Lyndsay Christensen, Jose Donato, Jing Xia, Mark L. Evans, Carol Elias, Jeffrey W. Dalley, Denis I. Burdakov, Martin G. Myers, Lora K. Heisler
Journal: Cell Metabolism (2011)
Statistically significant or clinically useful? From population studies to patient care
Authors: V. Brusasco
Journal: European Respiratory Journal (2009)

In the last few years, great attention has been paid to a variety of comorbid conditions that are frequently observed in patients with known chronic obstructive pulmonary disease (COPD). Although the term comorbidity literally refers to a disease occurring simultaneously with and usually independently of another medical condition 1, it has been used to lend support to the hypothesis that COPD is a component of a chronic systemic inflammatory syndrome involving several organs 2 and to a change in the COPD definition 3. In this scenario, systemic inflammation would be a cause rather than a consequence of COPD and the C-reactive protein (CRP) has been proposed as one of the major culprits 4. However attractive, this hypothesis was only based on cross-sectional population studies, which were designed to show associations but not causality.

Among the reported COPD comorbidities are both cachexia and obesity. Whereas the former can be regarded as a consequence of severe COPD, the relationship between obesity and COPD is not clear. In a large population study, Landbo et al. 5 found a monotonically inverse relationship between body mass index (BMI) and mortality in subjects with severe COPD, thus suggesting that optimal BMI in these patients is not between 21 and 25 kg·m−2, as in …
Investigation of the influence of extracellular matrix proteins on normal human melanocyte morphology and melanogenic activity
Authors: S. HEDLEY, D.J. GAWKRODGER, A.P. WEETMAN, S. MACNEIL
Journal: British Journal of Dermatology (1996)

Journal Article Investigation of the influence of extracellular matrix proteins on normal human melanocyte morphology and melanogenic activity Get access S. HEDLEY, S. HEDLEY University Department of Medicine, Clinical Sciences Centre. Northern General Hospital. Sheffield S5 7AU Search for other works by this author on: Oxford Academic Google Scholar D.J. GAWKRODGER, D.J. GAWKRODGER Department of Dermatology, Royal Hallamshire Hospital. Sheffield S10 2RX. U.K. Search for other works by this author on: Oxford Academic Google Scholar A.P. WEETMAN, A.P. WEETMAN University Department of Medicine, Clinical Sciences Centre. Northern General Hospital. Sheffield S5 7AU Search for other works by this author on: Oxford Academic Google Scholar S. MACNEIL S. MACNEIL University Department of Medicine, Clinical Sciences Centre. Northern General Hospital. Sheffield S5 7AU Dr S.MacNeil Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 135, Issue 6, 1 December 1996, Pages 888–897, https://doi.org/10.1046/j.1365-2133.1996.d01-1091.x Published: 01 December 1996 Article history Accepted: 15 April 1996 Published: 01 December 1996
Antibodies against<i>Porphyromonas gingivalis</i>in seropositive arthralgia patients do not predict development of rheumatoid arthritis
Authors: Menke de Smit, Lotte Arwen van de Stadt, Koen M J Janssen, Berber Doornbos-van der Meer, Arjan Vissink, Arie Jan van Winkelhoff, Elisabeth Brouwer, Johanna Westra, Dirkjan van Schaardenburg
Journal: Annals of the Rheumatic Diseases (2014)

Clinical studies point towards an association between periodontitis and rheumatoid arthritis (RA).1 ,2 A pathogenic role is suggested for Porphyromonas gingivalis .3 P gingivalis may contribute to the pathogenesis of RA by breaking immune tolerance through formation of (bacterial and human) citrullinated proteins, leading to anticitrullinated protein antibody production (ACPA).4 ,5 Since ACPA production precedes RA development6 and because P gingivalis IgG antibodies are long-term stable in untreated periodontitis patients,7 we investigated whether anti- P gingivalis antibody levels are prognostic for development of RA, by assessing these antibodies in a cohort of 289 adults at risk for RA. Patients with arthralgia and seropositivity for IgM-rheumatoid factor (IgM-RF) and/or ACPA were selected from a prospective follow-up study on arthritis development.8 They are further referred to as seropositive arthralgia patients (SAP); their median follow-up was 30 months (IQR 13–49).

Baseline sera were used for measurement of ACPA, IgM-RF, C-reactive protein (CRP) and HLA-DRB1 SE carrier status.8 IgA, IgG and IgM antibody levels against P gingivalis were determined by in-house ELISA with a pooled lysate of clinical isolates of P gingivalis as …